Acute Myocardial Infarction and Unstable Angina Patients With PCSK9 Inhibitor Usage Study
Status:
Recruiting
Trial end date:
2023-04-23
Target enrollment:
Participant gender:
Summary
Acute coronary syndrome (ACS) is a lethal disease, reduced low-density lipoprotein (LDL)
cholesterol due to inhibition of proprotein convertase subtilisin/kexin 9 (PCSK9) reduces
cardiovascular events and improve cardiovascular prognosis. we assuming that PCSK9 inhibitor
could bring metabolic change in serum, in order to investigate the metabolic modification, we
conduct this clinical trial.